(Trimethoprim/Sulfamethoxazole [TMP/SMX]) (Bactrim, Septra)

Category:

  • Antibiotic

Description:

  • Combination antibiotic (sulfonamide and folate antagonist)

Indications:

  • Urinary tract infections (pyelonephritis, cystitis) (E. coli, Klebsiella and Enterobacter species, M. morganii, P. mirabilis, P. vulgaris)

  • Shigella enteritis (S. flexneri, S. sonnei)

  • Pneumocystis carinii pneuomonia

  • Acute otitis media (children) (H. influenzae, S. pneumoniae)

  • Acute exacerbations of chronic bronchitis (adults) (H. influenzae, S. pneumoniae)

  • Traveler’s diarrhea (E. coli)

  • Acute and chronic pancreatitis

  • Unlabeled uses:

  • Cholera

  • Salmonella-type infections

  • Nocardiosis

Contraindications:

  • Hypersensitivity to sulfa-related medications (sulfonylureas, thiazide and loop diuretics, carbonic anhydrase inhibitors, sunscreens with PABA, local anesthetics)

  • Pregnancy at term

  • Lactation

  • Infants less than 2 months old (except congenital toxoplasmosis as adjunct with pyrimethamine)

  • Megaloblastic anemia caused by folate deficiency

Precautions:

  • Pregnancy category C

  • Sulfonamides have been associated with severe hypersensitivity reactions and death.

  • Serious blood disorders (agranulocytosis, hepatocellular necrosis, aplastic anemia) have been associated with sulfonamides.  Perform complete blood counts.  Symptoms of sore throat, fever, pallor, purpura or jaundice may be early signs of serious blood disorders.

  • Use with caution in patients with severe asthma or allergies.

  • Hemolytic anemia may occur in patients with G-6-PD deficiency.

  • Photosensitization may occur, caution patients to use protective measures against ultraviolet or sunlight until tolerance is determined.

  • Sulfonamides increase the effect of oral anticoagulants (warfarin).

  • Take with a full glass of water and increase fluid intake to 2-3 liters per day.

  • Complete full course of therapy.

  • Parenteral therapy may cause extravascular infiltration and local irritation.

  • For oral suspension; store at room temperature, shake well before using

Adverse Reactions (Side Effects):

  • Headache, peripheral neuropathy, depression

  • Tinnitis, vertigo

  • Nausea, emesis, abdominal pain, anorexia, diarrhea

  • Hepatitis, pancreatitis, stomatitis

  • Urticaria, Stevens-Johnson type erythema multiforme

  • Crystalluria, elevated creatinine

  • Drug fever, chills

  • Photosensitivity 

Dosage:

Administered orally (tablets and suspension) and IV injection

  • Urinary tract infections, shigellosis, acute otitis media:

    • Adults: 160mg TMP and 800mg SMX q12h for 10-14 days (shigellosis for 5 days)

    • Children (> 2months): 8mg/kg TMP and 40mg/kg SMX in divided doses q12h for 10 days (shigellosis for 5 days)

  • Traveler’s diarrhea:

    • Adults: 160mg TMP and 800mg SMX q12h for 5 days

  • Acute exacerbations of chronic bronchitis

    • Adults: 160mg TMP and 800mg SMX q12h for 14 days

  • Pneumocystis carinii pneumonia:

    • Adults: 15-20 mg/kg TMP and 100mg/kg SMX in divided doses q6h for 14-21 days

  • Parenteral:

    • Adults and Children > 2 months: 15-20 mg/kg/day (based on TMP dose) in 3-4 divided doses q6-8h for up to 14 days

  • Prophylaxis:

    • Adults: 160mg TMPO and 800mg SMX given orally q24h

    • Children > 2 months: 150mg/m2 TMP and 750mg/m2 SMX given orally in equally divided doses twice a day on three consecutive days of the week (do not exceed 320mg TMP and 1600mg SMX per day)

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site